

July 27, 2023

James D. Swift, M.D.
Chief Executive Officer
Pediatrix Medical Group, Inc.
1301 Concord Terrace
Sunrise, FL 33323

Group, Inc.

Statement on Schedule 14A
2023

Re: Pediatrix Medical
Definitive Proxy
Filed March 31,
File No. 001-12111

Dear James D. Swift:

We have limited our review of your most recent definitive proxy statement to those issues we have addressed in our comments. Please respond to these comments by confirming that you will revise your future proxy disclosures in accordance with the topics discussed below.

Definitive Proxy Statement on Schedule 14A filed March 31, 2023
Pay Versus Performance, page 58

1. We note that you have included Income (Loss) from Continuing Operations in column (h) of your pay versus performance table in lieu of net income (loss) as required by Regulation S-K Item 402(v)(2)(v). Please include net income (loss), as reported in your audited GAAP financial statements, in column (h) for all years covered by the table. Refer to Regulation S-K Compliance and Disclosure Interpretations Questions 128D.08 and 128D.09. Please note that you may voluntarily provide supplemental measures of compensation or financial performance, so long as any additional disclosure is clearly identified as supplemental, not misleading, and not presented with greater prominence than the required disclosure.

James D. Swift, M.D.
FirstName LastNameJames D. Swift, M.D.
Pediatrix Medical Group, Inc.
Comapany NamePediatrix Medical Group, Inc.
July 27, 2023

July 27,
Page 2 2023 Page 2
FirstName LastName

Please contact Eric Envall at 202-551-3234 or Charlie Guidry at 202-551-3621 with any questions.

Sincerely,
Division of
Disclosure Review

Corporation Finance
Program